Recurrent Mild Acute Rejections and Donor-specific Antibodies As Risk Factors for Cardiac Allograft Vasculopathy in a National Pediatric Heart Transplant Cohort

Overview

Journal Transplant Direct

Publisher Wolters Kluwer

Specialty General Surgery

Date 2023 Sep 25

PMID 37745950

Authors

Anu K Kaskinen

Juuso Tainio

Jaana I Pihkala

Juha P Perasaari

Jouni Lauronen

Alireza Raissadati

Jussi M Merenmies

Hannu J Jalanko

Timo Jahnukainen

Affiliations

Soon will be listed here.

Abstract

Background: Immune-mediated factors such as acute cellular rejections and donor-specific antibodies (DSAs) are risk factors for cardiac allograft vasculopathy (CAV). We studied a national cohort with a unified setting and thorough protocol endomyocardial biopsy (EMB) data for an association between cellular rejections, especially when mild and recurrent, and DSAs with CAV in pediatric heart transplant (HTx) patients.

Methods: This is a retrospective, national cohort study of 94 pediatric HTxs performed between 1991 and 2019 and followed until December 31, 2020. Diagnosis of CAV was based on reevaluation of angiographies. Protocol and indication EMB findings with other patient data were collected from medical records. Associations between nonimmune and immune-mediated factors and CAV were analyzed with univariable and multivariable Cox regression analyses.

Results: Angiographies performed on 76 patients revealed CAV in 23 patients (30%). Altogether 1138 EMBs (92% protocol biopsies) were performed on 78 patients (83%). During the first posttransplant year, grade 1 rejection (G1R) appeared in 45 patients (58%), and recurrent (≥2) G1R findings in 14 patients (18%). Pretransplant DSAs occurred in 13 patients (17%) and posttransplant DSAs in 37 patients (39%). In univariable analysis, pretransplant DSAs, appearance and recurrence of G1R findings, and total rejection score during the first posttransplant year, as well as recurrent G1R during follow-up, were all associated with CAV. In multivariable analysis, pretransplant DSAs and recurrent G1R during the first posttransplant year were found to be associated with CAV.

Conclusions: Our results indicate that pretransplant DSA and recurrent G1R findings, especially during the first posttransplant year, are associated with CAV after pediatric HTx.

References

Irving C, Carter V, Gennery A, Parry G, Griselli M, Hasan A . Effect of persistent versus transient donor-specific HLA antibodies on graft outcomes in pediatric cardiac transplantation. J Heart Lung Transplant. 2015; 34(10):1310-7. DOI: 10.1016/j.healun.2015.05.001. View

Dipchand A, Webber S, Mason K, Feingold B, Bentlejewski C, Mahle W . Incidence, characterization, and impact of newly detected donor-specific anti-HLA antibody in the first year after pediatric heart transplantation: A report from the CTOTC-04 study. Am J Transplant. 2018; 18(9):2163-2174. PMC: 6092243. DOI: 10.1111/ajt.14691. View

Urschel S, Ballweg J, Cantor R, Koehl D, Reinhardt Z, Zuckerman W . Clinical outcomes of children receiving ABO-incompatible versus ABO-compatible heart transplantation: a multicentre cohort study. Lancet Child Adolesc Health. 2021; 5(5):341-349. DOI: 10.1016/S2352-4642(21)00023-7. View

Laks J, Dipchand A . Cardiac allograft vasculopathy: A review. Pediatr Transplant. 2022; 26(3):e14218. DOI: 10.1111/petr.14218. View

Mulla N, Johnston J, Vander Dussen L, Beeson W, Chinnock R, Bailey L . Late rejection is a predictor of transplant coronary artery disease in children. J Am Coll Cardiol. 2001; 37(1):243-50. DOI: 10.1016/s0735-1097(00)01037-8. View

Kobayashi D, Du W, LEcuyer T . Predictors of cardiac allograft vasculopathy in pediatric heart transplant recipients. Pediatr Transplant. 2013; 17(5):436-40. DOI: 10.1111/petr.12095. View

Braunlin E, Hunter D, Canter C, Gutierrez F, Ring W, Olivari M . Coronary artery disease in pediatric cardiac transplant recipients receiving triple-drug immunosuppression. Circulation. 1991; 84(5 Suppl):III303-9. View

Stewart S, Winters G, Fishbein M, Tazelaar H, Kobashigawa J, Abrams J . Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant. 2005; 24(11):1710-20. DOI: 10.1016/j.healun.2005.03.019. View

Mehra M, Crespo-Leiro M, Dipchand A, Ensminger S, Hiemann N, Kobashigawa J . International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy-2010. J Heart Lung Transplant. 2010; 29(7):717-27. DOI: 10.1016/j.healun.2010.05.017. View

10.

Frank R, Molina M, Goldberg L, Wald J, Kamoun M, Lal P . Circulating donor-specific anti-human leukocyte antigen antibodies and complement C4d deposition are associated with the development of cardiac allograft vasculopathy. Am J Clin Pathol. 2014; 142(6):809-15. DOI: 10.1309/AJCPTLBEU5BQ8SHN. View

11.

Addonizio L, Hsu D, Douglas J, Kichuk M, Michler R, Quaegebeur J . Decreasing incidence of coronary disease in pediatric cardiac transplant recipients using increased immunosuppression. Circulation. 1993; 88(5 Pt 2):II224-9. View

12.

Su J, Baxter-Lowe L, Kantor P, Szmuszkovicz J, Menteer J . The clinical impact of donor-specific antibodies on antibody-mediated rejection and long-term prognosis after heart transplantation. Curr Opin Organ Transplant. 2019; 24(3):245-251. DOI: 10.1097/MOT.0000000000000636. View

13.

Clerkin K, Farr M, Restaino S, Zorn E, Latif F, Vasilescu E . Donor-specific anti-HLA antibodies with antibody-mediated rejection and long-term outcomes following heart transplantation. J Heart Lung Transplant. 2016; 36(5):540-545. PMC: 5654313. DOI: 10.1016/j.healun.2016.10.016. View

14.

Sirota M, Heyrend C, Ou Z, Masotti S, Griffiths E, Molina K . Impact of tacrolimus variability on pediatric heart transplant outcomes. Pediatr Transplant. 2021; 25(7):e14043. DOI: 10.1111/petr.14043. View

15.

Moayedi Y, Fan C, Tinckam K, Ross H, McCaughan J . De novo donor-specific HLA antibodies in heart transplantation: Do transient de novo DSA confer the same risk as persistent de novo DSA?. Clin Transplant. 2018; 32(11):e13416. DOI: 10.1111/ctr.13416. View

16.

Seipelt I, Pahl E, Seipelt R, Mavroudis C, Backer C, Stellmach V . Neointimal inflammation and adventitial angiogenesis correlate with severity of cardiac allograft vasculopathy in pediatric recipients. J Heart Lung Transplant. 2005; 24(8):1039-45. DOI: 10.1016/j.healun.2004.07.005. View

17.

Pahl E, Naftel D, Kuhn M, Shaddy R, Morrow W, Canter C . The impact and outcome of transplant coronary artery disease in a pediatric population: a 9-year multi-institutional study. J Heart Lung Transplant. 2005; 24(6):645-51. DOI: 10.1016/j.healun.2004.03.021. View

18.

Feingold B, Irving C, Tatum G, Webber S . Prognostic significance of recurrent grade 1B rejection in the first year after pediatric cardiac transplantation: a case for reinstatement of the 1B rejection grade. Pediatr Transplant. 2011; 15(6):589-93. PMC: 3172690. DOI: 10.1111/j.1399-3046.2011.01530.x. View

19.

Barten M, Schulz U, Beiras-Fernandez A, Berchtold-Herz M, Boeken U, Garbade J . The clinical impact of donor-specific antibodies in heart transplantation. Transplant Rev (Orlando). 2018; 32(4):207-217. DOI: 10.1016/j.trre.2018.05.002. View

20.

Asimacopoulos E, Garbern J, Gauvreau K, Blume E, Daly K, Singh T . Association of Clinical Rejection Versus Rejection on Protocol Biopsy With Cardiac Allograft Vasculopathy in Pediatric Heart Transplant Recipients. Transplantation. 2019; 104(1):e31-e37. DOI: 10.1097/TP.0000000000002983. View